Evaluating Determinants of Treatment Outcomes Among Tuberculosis Patients in the Mining District of Butha Buthe, Lesotho

Overview

Journal IJID Reg

Specialty Infectious Diseases

Date 2023 Jan 3

PMID 36593894

Authors

Veranyuy D Ngah

Motlatsi Rangoanana

Isaac Fwemba

Llang Maama

Sele Maphalale

Mabatho Molete

Retselisitsoe Ratikoane

Modupe Ogunrombi

Justine Daramola

Peter S Nyasulu

Affiliations

Soon will be listed here.

Abstract

Background: Before the COVID-19 pandemic, tuberculosis (TB) was the leading infectious cause of death globally. In low- and middle-income countries (LMIC) including Lesotho, treatment outcome is lower than the recommended rate and poor TB treatment outcomes remain a programmatic challenge. The aim of this study was to determine unfavourable treatment outcomes and associated risk factors among TB patients in Butha Buthe district.

Methods: This was a retrospective record review of TB patients registered between January 2015 and December 2020. Data were collected from TB registers and patients' files and entered Microsoft Excel 2012. Analysis was conducted using R and INLA statistical software. Descriptive statistics were presented as frequencies and percentages. The differences between groups were compared using Pearson's test in bivariate analysis. Frailty Cox proportional hazards model was used to determine the risk of unfavourable outcomes among the variables.

Results: A total of 1792 TB patients were enrolled in the study with about 70% males (1,257). Majority (71.7%) of the patients were between 20 and 59 years old, with 48% of the patients being unemployed. Almost a quarter of the patients (23.1%) had unfavourable outcomes with death (342 patients) being the most common unfavourable outcome. Our study has shown that patients older than 59 years, and unemployment increased the risk of having unfavourable treatment outcomes. Death was the most common unfavourable outcome followed by lost-to-follow up. We also observed that the patients in the initiation phase of treatment died at a faster rate compared to those in the continuation phase (p=0.02).

Conclusion: TB treatment programs should have efficient follow-up methods geared more toward elderly patients. Active case finding to identify population at risk should be part of a TB program which would improve early diagnosis and treatment initiation. Patients in the intensive phase of the treatment program should be monitored more closely to determine adverse drug effects and nutritional requirement to prevent death during this phase of treatment.

References

Carrol E, Clark J, Cant A . Non-pulmonary tuberculosis. Paediatr Respir Rev. 2003; 2(2):113-9. DOI: 10.1053/prrv.2000.0118. View

Osorio D, Munyangaju I, Nacarapa E, Nhangave A, Ramos-Rincon J . Predictors of unfavourable tuberculosis treatment outcome in Bilene District, Gaza Province, Mozambique: A retrospective analysis, 2016 - 2019. S Afr Med J. 2022; 112(3):234-239. View

Charoensakulchai S, Lertpheantum C, Aksornpusitpong C, Trakulsuk P, Sakboonyarat B, Rangsin R . Six-year trend and risk factors of unsuccessful pulmonary tuberculosis treatment outcomes in Thai Community Hospital. BMC Res Notes. 2021; 14(1):89. PMC: 7941995. DOI: 10.1186/s13104-021-05504-z. View

Ananthakrishnan R, Kumar K, Ganesh M, Kumar A, Krishnan N, Swaminathan S . The profile and treatment outcomes of the older (aged 60 years and above) tuberculosis patients in Tamilnadu, South India. PLoS One. 2013; 8(7):e67288. PMC: 3704605. DOI: 10.1371/journal.pone.0067288. View

Murali S, Krishnamoorthy Y, Knudsen S, Roy G, Ellner J, Horsburgh C . Comparison of profile and treatment outcomes between elderly and non-elderly tuberculosis patients in Puducherry and Tamil Nadu, South India. PLoS One. 2021; 16(8):e0256773. PMC: 8396735. DOI: 10.1371/journal.pone.0256773. View

Katende B, Esterhuizen T, Dippenaar A, Warren R . Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes. Sci Rep. 2020; 10(1):1917. PMC: 7002499. DOI: 10.1038/s41598-020-58690-4. View

Nanzaluka F, Chibuye S, Kasapo C, Langa N, Nyimbili S, Moonga G . Factors associated with unfavourable tuberculosis treatment outcomes in Lusaka, Zambia, 2015: a secondary analysis of routine surveillance data. Pan Afr Med J. 2019; 32:159. PMC: 6609856. DOI: 10.11604/pamj.2019.32.159.18472. View

Wondale B, Medihn G, Teklu T, Mersha W, Tamirat M, Ameni G . A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia. BMC Res Notes. 2017; 10(1):680. PMC: 5715540. DOI: 10.1186/s13104-017-3020-z. View

Zhang M, Zhou L, Zhang Y, Chen B, Peng Y, Wang F . Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res. 2021; 26(1):31. PMC: 8019161. DOI: 10.1186/s40001-021-00502-0. View

10.

Nidoi J, Muttamba W, Walusimbi S, Imoko J, Lochoro P, Ictho J . Impact of socio-economic factors on Tuberculosis treatment outcomes in north-eastern Uganda: a mixed methods study. BMC Public Health. 2021; 21(1):2167. PMC: 8620143. DOI: 10.1186/s12889-021-12056-1. View

11.

Faustini A, Hall A, Perucci C . Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005; 26(3):503-10. DOI: 10.1183/09031936.05.00103504. View

12.

Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov A, Tupasi T . Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004; 8(11):1382-4. View

13.

Andom A, Gilbert H, Ndayizigiye M, Mukherjee J, Nthunya J, Marole T . Understanding reasons for suboptimal tuberculosis screening in a low-resource setting: A mixed-methods study in the Kingdom of Lesotho. PLOS Glob Public Health. 2023; 2(3):e0000249. PMC: 10021370. DOI: 10.1371/journal.pgph.0000249. View

14.

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode S . Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020; 8(4):383-394. PMC: 7384398. DOI: 10.1016/S2213-2600(20)30047-3. View

15.

Lee J . Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015; 78(2):47-55. PMC: 4388900. DOI: 10.4046/trd.2015.78.2.47. View

16.

Muluye A, Kebamo S, Teklie T, Alemkere G . Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in East Wollega, Western Ethiopia. PLoS One. 2018; 13(10):e0206227. PMC: 6203372. DOI: 10.1371/journal.pone.0206227. View

17.

Ahmad S, Mokaddas E . Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2013; 7(2):75-91. DOI: 10.1016/j.jiph.2013.09.001. View

18.

Nakafeero Simbwa B, Katamba A, Katana E, Laker E, Nabatanzi S, Sendaula E . The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study. BMC Infect Dis. 2021; 21(1):950. PMC: 8442422. DOI: 10.1186/s12879-021-06675-7. View

19.

Woldemichael B, Darega J, Dida N, Tesfaye T . Treatment outcomes of tuberculosis patients and associated factors in Bale Zone, Southeast Ethiopia: a retrospective study. J Int Med Res. 2021; 49(2):300060520984916. PMC: 7871063. DOI: 10.1177/0300060520984916. View

20.

Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N . Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2016; 61(2). PMC: 5278698. DOI: 10.1128/AAC.01299-16. View